Literature DB >> 17670509

Thymoma is associated with relapse of symptoms after transsternal thymectomy for myasthenia gravis.

Han-Shui Hsu1, Chien-Sheng Huang, Biing-Shiun Huang, Hui-Chen Lee, Ko-Pei Kao, Wen-Hu Hsu, Min-Hsiung Huang.   

Abstract

Thymectomy is considered a therapeutic option for patients with myasthenia gravis. A myasthenic patient who has not received any treatment for years and shows no signs or symptoms of the disease after operation is still susceptible to a recurrence of myasthenic symptoms. To investigate which factors are related to relapse of symptoms in patients having thymectomy, we conduct a retrospective review in the patients who had experienced complete remission after thymectomy. Complete remission was achieved in 92 of 154 patients who received extended transsternal thymectomy for myasthenia gravis. Among these 92 patients, 20 patients had relapse of symptoms and needed medication again after complete remission was achieved (21.7%). Ten of 22 patients in the thymomatous group had relapse of symptom after complete remission was achieved, while only 10 of 70 patients in the nonthymomatous group had relapse of symptom (P=0.006). Multivariate Cox regression analysis revealed that thymoma was an independent factor for the development of relapse of symptoms. In conclusion, thymoma is an adverse prognostic factor for the MG patients who have experienced complete remission after thymectomy. The patients with thymoma had a greater possibility to develop relapse of symptoms than the patients without thymoma.

Entities:  

Year:  2005        PMID: 17670509     DOI: 10.1510/icvts.2005.116616

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  5 in total

1.  Thymectomy for Myasthenia Gravis: A 10-year Review of Cases at the Hospital Universiti Sains Malaysia.

Authors:  Julieana Muhammed; Chui Yin Chen; Wan Hazabbah Wan Hitam; Mohamad Ziyadi Ghazali
Journal:  Malays J Med Sci       Date:  2016-06-30

2.  Modified maximal thymectomy for thymic epithelial tumors: predictors of survival and neurological outcome in patients with thymomatous myasthenia gravis.

Authors:  Christos Prokakis; Efstratios Koletsis; Efstratios Apostolakis; Vasiliki Zolota; Elisabeth Chroni; Nikolaos Baltayiannis; Antonios Chatzimichalis; Dimitrios Dougenis
Journal:  World J Surg       Date:  2009-08       Impact factor: 3.352

3.  Preoperative high-dose steroid has long-term beneficial effects for myasthenia gravis.

Authors:  Syuichi Tetsuka; Ken-Ichi Fujimoto; Kunihiko Ikeguchi
Journal:  Neurol Res Int       Date:  2013-07-14

4.  Clinical predictors for the prognosis of myasthenia gravis.

Authors:  Lili Wang; Yun Zhang; Maolin He
Journal:  BMC Neurol       Date:  2017-04-19       Impact factor: 2.474

5.  Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis.

Authors:  Xiaoling Zhou; Xiaoyuan Wang; Yanzheng Gu; Lan Chen; Yueping Shen; Jingluan Tian; Chen Shujun; Mingyuan Wang; Xiaoyu Duan; Hanqing Gao; Xiaopei Ji; Qi Fang; Xueguang Zhang; Qun Xue
Journal:  J Immunol Res       Date:  2022-02-28       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.